SCHEMBL4849592

SCHEMBL4849592

CCOC(=O)c1c(N2CCN(C(=O)c3ccco3)CC2)c2cc(F)cnc2n(Cc2cccc(F)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.49
KDM4E B2RXH2 4/20 0.49
LDHA P00338 1/20 0.43
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPGD P15428 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
LMNA P02545 2/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
HTT P42858 3/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 2/20 0.42
ABCB1 P08183 1/20 0.42
P2RY12 Q9H244 1/20 0.42
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854242 0.94 ALDH1A1 (0.44) ALDH1A1KDM4EPOLBMAPK1CYP1A2
SCHEMBL27631477 0.89 ALDH1A1 (0.53) ALDH1A1KDM4ELDHAMAPK1HPGD
SCHEMBL4854020 0.87 ALDH1A1 (0.43) ALDH1A1KDM4EPOLBMAPK1CYP1A2
SCHEMBL4855096 0.87 P2RY12 (0.41) ALDH1A1KDM4EKMT2AMEN1P2RY12
SCHEMBL14195153 0.86 ALDH1A1 (0.48) ALDH1A1KDM4ELDHAPOLBMAPK1
SCHEMBL14195166 0.86 ALDH1A1 (0.48) ALDH1A1KDM4ELDHAPOLBMAPK1
SCHEMBL4851839 0.84 ALDH1A1 (0.52) ALDH1A1KDM4ELDHAHPGDNPSR1
SCHEMBL14195136 0.84 ALDH1A1 (0.49) ALDH1A1KDM4ELDHAPOLBMAPK1
SCHEMBL27631543 0.84 ALDH1A1 (0.45) ALDH1A1KDM4EPOLBMAPK1HPGD
SCHEMBL14194796 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361760-B2 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases AVANIR PHARMACEUTICALS (US) 2008-04-22 US disclosed
US-20070191388-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2007-08-16 US disclosed
EP-1656376-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES Avanir Pharmaceuticals (US) 2006-05-17 EP disclosed
US-20050124604-A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases AVANIR PHARMACEUTICALS, INC. 2005-06-09 US disclosed
WO-2005021546-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191388-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES MIF, MSR1, SLC11A2 ALDH1A1 2477/4885KDM4E 3601/4885LDHA 2535/4885
US-20050124604-A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases MIF, MSR1, SLC11A2 ALDH1A1 2477/4885KDM4E 3601/4885LDHA 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.